8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Feb 24, 2026·SEC
BridgeBio Pharma, Inc.(BBIO)Earnings, Financials & Key Ratios
BBIO•NASDAQ
$67.45
$13.08B mkt cap·Price updated May 7, 2026
AboutBridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Show more
- Revenue$502M+126.3%
- EBITDA-$560M+4.6%
- Net Income-$729M-36.1%
- EPS (Diluted)-3.79-31.6%
- Gross Margin94.37%-4.0%
- EBITDA Margin-111.55%+57.8%
- Operating Margin-113.35%+57.6%
- Net Margin-145.26%+39.8%
- ROIC-524%
- Interest Coverage-12.84-187.9%
BBIO Key Insights
BridgeBio Pharma, Inc. (BBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 127.4%
✗Weaknesses
- ✗Profits declining 10.2% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BBIO Price & Volume
BridgeBio Pharma, Inc. (BBIO) stock price & volume — 10-year historical chart
Loading chart...
BBIO Growth Metrics
BridgeBio Pharma, Inc. (BBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years127.44%
3 Years86.3%
TTM344.25%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-6.23%
Return on Capital
10 Years-80.14%
5 Years-93.68%
3 Years-105.5%
Last Year-80.55%
BBIO Recent Earnings
BridgeBio Pharma, Inc. (BBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 24, 2026EPS
$1.00
Est $0.71
-40.2%
Revenue
$154M
Est $147M
+5.0%
Q4 2025
Oct 29, 2025EPS
$0.95
Est $0.88
-8.0%
Revenue
$121M
Est $148M
-18.5%
Q3 2025
Aug 5, 2025EPS
$0.95
Est $0.83
-14.5%
Revenue
$111M
Est $108M
+2.3%
Q2 2025
Apr 29, 2025EPS
$0.88
Est $1.00
+12.0%
Revenue
$117M
Est $68M
+70.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $1.00vs $0.71-40.2% | $154Mvs $147M+5.0% |
| Q4 2025 | Oct 29, 2025 | $0.95vs $0.88-8.0% | $121Mvs $148M-18.5% |
| Q3 2025 | Aug 5, 2025 | $0.95vs $0.83-14.5% | $111Mvs $108M+2.3% |
| Q2 2025 | Apr 29, 2025 | $0.88vs $1.00+12.0% | $117Mvs $68M+70.5% |
Based on last 12 quarters of dataView full earnings history →
BBIO Peer Comparison
BridgeBio Pharma, Inc. (BBIO) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARRY | 1.25B | 8.20 | -11.23 | 40.22% | -5.56% | -20.64% | 2.94 | |
 RCUS | 2.5B | 24.80 | -7.54 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 VRTX | 108.1B | 425.00 | 27.74 | 9.57% | 35.4% | 23.93% | 0.21 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 |
Compare BBIO vs Peers
BridgeBio Pharma, Inc. (BBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BBIO Income Statement
BridgeBio Pharma, Inc. (BBIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 40.56M | 8.25M | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M | 566.04M |
| Revenue Growth % | - | - | - | -79.66% | 745.14% | 11.38% | -88.02% | 2285.27% | 126.26% | 344.25% |
| Cost of Goods Sold | 260K | 0 | 2.5M | 0 | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M | 27.84M |
| COGS % of Revenue | - | - | 6.16% | - | 4.47% | 4.42% | 26.29% | 1.75% | 5.63% | - |
| Gross Profit | -260K▲ 0% | 0▲ 100.0% | 38.06M▲ 0% | 8.25M▼ 78.3% | 66.6M▲ 707.4% | 74.21M▲ 11.4% | 6.86M▼ 90.8% | 218.02M▲ 3079.6% | 473.81M▲ 117.3% | 538.2M▲ 0% |
| Gross Margin % | - | - | 93.84% | 100% | 95.53% | 95.58% | 73.71% | 98.25% | 94.37% | 95.08% |
| Gross Profit Growth % | - | 100% | - | -78.33% | 707.39% | 11.43% | -90.76% | 3079.58% | 117.32% | - |
| Operating Expenses | 43.86M | 183.66M | 304.3M | 482.73M | 643.23M | 586.42M | 614.23M | 811M | 1.04B | 1.12B |
| OpEx % of Revenue | - | - | 750.25% | 5851.99% | 922.65% | 755.22% | 6602.46% | 365.48% | 207.72% | - |
| Selling, General & Admin | 13.3M | 43.59M | 94.35M | 145.68M | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M | 612.67M |
| SG&A % of Revenue | - | - | 232.63% | 1766.08% | 275.7% | 184.41% | 1618.73% | 130.21% | 110.57% | - |
| Research & Development | 30.56M | 140.07M | 209.95M | 337.05M | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M | 492.74M |
| R&D % of Revenue | - | - | 517.62% | 4085.91% | 646.94% | 514.45% | 4898.54% | 228.24% | 95.11% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 43.77M | 7.93M | 15.61M | 10.22M | 2.8M |
| Operating Income | -43.86M▲ 0% | -183.66M▼ 318.8% | -266.24M▼ 45.0% | -474.48M▼ 78.2% | -576.63M▼ 21.5% | -512.2M▲ 11.2% | -607.37M▼ 18.6% | -592.97M▲ 2.4% | -569.09M▲ 4.0% | -570.67M▲ 0% |
| Operating Margin % | - | - | -656.41% | -5751.99% | -827.12% | -659.65% | -6528.75% | -267.22% | -113.35% | -100.82% |
| Operating Income Growth % | - | -318.76% | -44.96% | -78.22% | -21.53% | 11.17% | -18.58% | 2.37% | 4.03% | - |
| EBITDA | -43.6M | -183.41M | -265.38M | -473.03M | -570.79M | -505.43M | -600.88M | -586.9M | -560.09M | -562.96M |
| EBITDA Margin % | - | - | -654.29% | -5734.34% | -818.73% | -650.93% | -6458.95% | -264.49% | -111.55% | -99.45% |
| EBITDA Growth % | - | -320.7% | -44.69% | -78.24% | -20.67% | 11.45% | -18.88% | 2.33% | 4.57% | 18.64% |
| D&A (Non-Cash Add-back) | 260K | 245K | 859K | 1.46M | 5.84M | 6.77M | 6.49M | 6.08M | 9M | 7.71M |
| EBIT | -43.82M | -183.66M | -279.82M | -468.83M | -539.68M | -404.21M | -571.96M | -442.9M | -681.88M | -504M |
| Net Interest Income | 26K | -543K | 150K | -32.64M | -45.65M | -72.9M | -63.25M | -82.04M | -33.25M | -46.91M |
| Interest Income | 39K | 2M | 8.91M | 4.01M | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M | 20.71M |
| Interest Expense | 13K | 2.55M | 8.77M | 36.66M | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M | 48.43M |
| Other Income/Expense | 26K | 14.21M | -22.34M | -31.01M | -9.82M | 27.55M | -45.88M | 50.78M | -165.9M | -158.75M |
| Pretax Income | -43.83M▲ 0% | -169.45M▼ 286.6% | -288.58M▼ 70.3% | -505.49M▼ 75.2% | -586.45M▼ 16.0% | -484.65M▲ 17.4% | -653.25M▼ 34.8% | -542.19M▲ 17.0% | -734.99M▼ 35.6% | -729.42M▲ 0% |
| Pretax Margin % | - | - | -711.5% | -6127.87% | -841.2% | -624.17% | -7021.94% | -244.34% | -146.39% | -128.86% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.15M | 555K | 555K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.21% | -0.08% | -0.08% |
| Net Income | -30.57M▲ 0% | -130.75M▼ 327.8% | -260.44M▼ 99.2% | -448.72M▼ 72.3% | -562.54M▼ 25.4% | -481.18M▲ 14.5% | -643.2M▼ 33.7% | -535.76M▲ 16.7% | -729.31M▼ 36.1% | -725.93M▲ 0% |
| Net Margin % | - | - | -642.1% | -5439.74% | -806.9% | -619.7% | -6913.92% | -241.44% | -145.26% | -128.25% |
| Net Income Growth % | - | -327.77% | -99.19% | -72.3% | -25.36% | 14.46% | -33.67% | 16.7% | -36.13% | -8.68% |
| Net Income (Continuing) | -43.83M | -169.45M | -288.58M | -505.49M | -586.45M | -484.65M | -653.25M | -543.35M | -735.54M | -729.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 3.33M | 62.48M | 67.52M | 49.98M | 4.83M | 9.69M | 11.72M | 10.29M | -570K | -951K |
| EPS (Diluted) | -0.33▲ 0% | -1.42▼ 330.3% | -2.48▼ 74.6% | -4.10▼ 65.3% | -3.90▲ 4.9% | -3.35▲ 14.1% | -3.95▼ 17.9% | -2.88▲ 27.1% | -3.79▼ 31.6% | -3.73▲ 0% |
| EPS Growth % | - | -330.3% | -74.65% | -65.32% | 4.88% | 14.1% | -17.91% | 27.09% | -31.6% | -6.23% |
| EPS (Basic) | -0.33 | -1.42 | -2.48 | -4.10 | -3.90 | -3.35 | -3.95 | -2.88 | -3.79 | - |
| Diluted Shares Outstanding | 92.33M | 92.33M | 105.1M | 118M | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M | 194.79M |
| Basic Shares Outstanding | 92.33M | 92.33M | 105.1M | 118M | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M | 194.79M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BBIO Balance Sheet
BridgeBio Pharma, Inc. (BBIO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 97.13M | 445.22M | 568.62M | 642.82M | 888.86M | 548.85M | 477.59M | 720.69M | 753.68M | 1.18B |
| Cash & Short-Term Investments | 92M | 436.09M | 545.99M | 607.09M | 836.66M | 471.92M | 434.88M | 681.1M | 587.48M | 940.19M |
| Cash Only | 92M | 436.09M | 363.77M | 356.08M | 393.77M | 376.69M | 375.94M | 681.1M | 570.12M | 879.89M |
| Short-Term Investments | 0 | 0 | 182.22M | 251.01M | 442.89M | 95.23M | 58.95M | 0 | 17.36M | 60.3M |
| Accounts Receivable | 0 | 0 | 2.85M | 0 | 19.75M | 17.08M | 1.75M | 4.72M | 139.44M | 205.23M |
| Days Sales Outstanding | - | - | 25.6 | - | 103.4 | 80.28 | 68.7 | 7.77 | 101.37 | 86.74 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.75M | 32.98M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | 345.38 | 336.07 |
| Other Current Assets | 889K | 0 | 0 | 139K | 177K | 37.93M | 27.65M | 3.83M | 0 | 0 |
| Total Non-Current Assets | 913K | 19.72M | 63.06M | 60.76M | 123.93M | 74.18M | 68.79M | 198.65M | 41.59M | 49.53M |
| Property, Plant & Equipment | 440K | 1.57M | 5.63M | 36.83M | 45.97M | 25.25M | 19.84M | 12.78M | 13.52M | 22.17M |
| Fixed Asset Turnover | - | - | 7.21x | 0.22x | 1.52x | 3.08x | 0.47x | 17.37x | 37.15x | 37.51x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 44.93M | 28.71M | 26.32M | 23.93M | 28.08M | 27.36M |
| Long-Term Investments | 381K | 17.05M | 31.14M | 0 | 0 | 0 | 0 | 143.75M | 81.44M | 344.84M |
| Other Non-Current Assets | 92K | 1.09M | 26.29M | 23.93M | 33.03M | 20.22M | 22.63M | 18.2M | -81.44M | -101.04M |
| Total Assets | 98.04M▲ 0% | 464.94M▲ 374.2% | 631.68M▲ 35.9% | 703.59M▲ 11.4% | 1.01B▲ 43.9% | 623.04M▼ 38.5% | 546.38M▼ 12.3% | 919.34M▲ 68.3% | 936.02M▲ 1.8% | 1.37B▲ 0% |
| Asset Turnover | - | - | 0.06x | 0.01x | 0.07x | 0.12x | 0.02x | 0.24x | 0.54x | 0.52x |
| Asset Growth % | - | 374.22% | 35.86% | 11.38% | 43.95% | -38.48% | -12.3% | 68.26% | 1.82% | 143.42% |
| Total Current Liabilities | 8.55M | 32.58M | 60.38M | 95.65M | 135.07M | 121.43M | 143.84M | 154.4M | 287.97M | 816.37M |
| Accounts Payable | 1.89M | 13.51M | 8.85M | 8.95M | 11.88M | 11.56M | 10.65M | 9.62M | 36.23M | 29.06M |
| Days Payables Outstanding | 2.65K | - | 1.29K | - | 1.39K | 1.23K | 1.59K | 905.25 | 467.7 | 360.93 |
| Short-Term Debt | 0 | 0 | 0 | 1.46M | 0 | 0 | 0 | 0 | 17.41M | 18.66M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 8.16M | 6.1M | 0 | 20.27M | 57.79M |
| Other Current Liabilities | 997K | 4.01M | 25.39M | 9.55M | 37.04M | 31.26M | 65.59M | 16.2M | 214.06M | 779.83M |
| Current Ratio | 11.36x | 13.67x | 9.42x | 6.72x | 6.58x | 4.52x | 3.32x | 4.67x | 2.62x | 2.62x |
| Quick Ratio | 11.36x | 13.67x | 9.42x | 6.72x | 6.58x | 4.52x | 3.32x | 4.67x | 2.52x | 2.52x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | -20.95 | 61.88 |
| Total Non-Current Liabilities | 144.18M | 533.87M | 95.32M | 500.05M | 1.74B | 1.75B | 1.75B | 2.22B | 2.72B | 2.82B |
| Long-Term Debt | 143.87M | 54.51M | 91.79M | 475.86M | 1.7B | 1.71B | 1.73B | 1.72B | 2.71B | 14.22M |
| Capital Lease Obligations | 0 | 0 | 0 | 14.68M | 17.43M | 12.27M | 8.98M | 4.7M | 3.81M | 11.26M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 312K | 479.36M | 3.53M | 9.52M | 22.07M | 26.64M | 9.36M | 496.47M | 244K | 3.65B |
| Total Liabilities | 152.73M | 566.44M | 155.7M | 595.7M | 1.88B | 1.87B | 1.89B | 2.38B | 3.01B | 3.64B |
| Total Debt | 143.87M | 54.51M | 91.79M | 495.79M | 1.73B | 1.72B | 1.74B | 1.73B | 2.73B | 18.66M |
| Net Debt | 51.87M | -381.58M | -271.98M | 139.71M | 1.33B | 1.35B | 1.36B | 1.05B | 2.16B | 18.66M |
| Debt / Equity | - | - | 0.19x | 4.60x | - | - | - | - | - | -0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
| Interest Coverage | -3370.69x | -72.11x | -31.92x | -12.79x | -11.54x | -5.03x | -7.04x | -4.46x | -12.84x | -10.41x |
| Total Equity | -54.69M▲ 0% | -101.5M▼ 85.6% | 475.98M▲ 568.9% | 107.89M▼ 77.3% | -865.58M▼ 902.3% | -1.24B▼ 43.8% | -1.34B▼ 7.8% | -1.46B▼ 8.6% | -2.08B▼ 42.5% | -2.27B▲ 0% |
| Equity Growth % | - | -85.61% | 568.93% | -77.33% | -902.31% | -43.83% | -7.84% | -8.57% | -42.5% | -203.18% |
| Book Value per Share | -0.59 | -1.10 | 4.53 | 0.91 | -6.00 | -8.44 | -8.25 | -7.83 | -10.53 | -11.65 |
| Total Shareholders' Equity | -58.02M | -163.99M | 408.45M | 57.91M | -870.41M | -1.25B | -1.35B | -1.47B | -2.08B | -2.27B |
| Common Stock | 3.41M | 6.59M | 124K | 125K | 154K | 157K | 181K | 196K | 202K | 204K |
| Retained Earnings | -61.43M | -170.58M | -440.03M | -888.75M | -1.44B | -1.92B | -2.56B | -3.1B | -3.82B | -3.99B |
| Treasury Stock | 0 | 0 | 0 | -75M | -275M | -275M | -275M | -275M | -323.28M | 0 |
| Accumulated OCI | -27K | -231K | 254K | 192K | -132K | -328K | 31K | 8K | 12K | -8K |
| Minority Interest | 3.33M | 62.48M | 67.52M | 49.98M | 4.83M | 9.69M | 11.72M | 10.29M | -570K | -951K |
BBIO Cash Flow Statement
BridgeBio Pharma, Inc. (BBIO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -40.49M | -136.64M | -253.59M | -399.71M | -497.93M | -419.49M | -527.72M | -520.73M | -445.91M | -445.91M |
| Operating CF Margin % | - | - | -625.21% | -4845.61% | -714.23% | -540.25% | -5672.58% | -234.66% | -88.81% | - |
| Operating CF Growth % | - | -237.49% | -85.58% | -57.62% | -24.57% | 15.75% | -25.8% | 1.33% | 14.37% | -96.59% |
| Net Income | -43.83M | -169.45M | -288.58M | -505.49M | -586.45M | -484.65M | -643.2M | -543.35M | -724.93M | -725.93M |
| Depreciation & Amortization | 260K | 245K | 859K | 3.09M | 5.84M | 6.77M | 6.49M | 6.08M | 5.97M | 5.99M |
| Stock-Based Compensation | 1.84M | 6.07M | 21.37M | 58.46M | 99.5M | 91.56M | 0 | 95.8M | 133.02M | 105.12M |
| Deferred Taxes | -260K | -14.89M | -859K | -1.87M | -30.93M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 260K | 18.89M | 24.54M | 31.16M | 18.5M | -61.25M | 103.93M | -111.3M | 191.09M | 103.16M |
| Working Capital Changes | 1.24M | 22.49M | -10.91M | 14.93M | -4.4M | 28.08M | 5.06M | 32.04M | -51.06M | 65.1M |
| Change in Receivables | 0 | 0 | -2.85M | 2.85M | -19.75M | 15.17M | 15.33M | -2.97M | -134.72M | -89.96M |
| Change in Inventory | 0 | 0 | 2.85M | -2.85M | 19.75M | 0 | 0 | 0 | -25.31M | -29.17M |
| Change in Payables | 1.58M | 16.7M | -4.66M | -735K | 2.83M | -349K | 2.78M | 1.51M | 26.61M | 1.87M |
| Cash from Investing | -464K | -21.04M | -217.25M | -52.99M | -200.83M | 453.15M | 54.03M | 60.78M | -24.49M | -65.03M |
| Capital Expenditures | -464K | -18.18M | -5.14M | -7.52M | -48.25M | -4.82M | -1.31M | -933K | -1.1M | -3.57M |
| CapEx % of Revenue | - | - | 12.67% | 91.14% | 69.2% | 6.21% | 14.04% | 0.42% | 0.22% | - |
| Acquisitions | 2.84M | -2.86M | -5.49M | 21.24M | -35M | 0 | 0 | -140K | 0 | 600K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -2.86M | 784K | -21.09M | 48.65M | 118.5M | -503K | -7.97M | -6.19M | -2.2M |
| Cash from Financing | 112.98M | 501.55M | 398.79M | 447.19M | 736.45M | -13.13M | 451.54M | 748.46M | 359.29M | 848.26M |
| Debt Issued (Net) | 4.13M | 56.38M | 36.94M | 550M | 1.08B | -20.49M | 0 | 476.58M | 385.5M | 285.55M |
| Equity Issued (Net) | 107.02M | 430.53M | 366.24M | -75.71M | -204.75M | 3.29M | 442.93M | 307.21M | -14.13M | 19.24M |
| Dividends Paid | -1.15M | 0 | -997K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -75.71M | -204.75M | -1.56M | -6.88M | -7.53M | -48.28M | -84.5M |
| Other Financing | 1.83M | 14.64M | -4.38M | -27.1M | -138.49M | 4.06M | 8.61M | -35.34M | -12.08M | 543.47M |
| Net Change in Cash | 72.03M▲ 0% | 343.87M▲ 377.4% | -72.05M▼ 121.0% | -5.52M▲ 92.3% | 37.69M▲ 783.0% | 20.52M▼ 45.6% | -22.15M▼ 208.0% | 288.51M▲ 1402.4% | -111.1M▼ 138.5% | 339.5M▲ 0% |
| Free Cash Flow | -40.95M▲ 0% | -154.82M▼ 278.1% | -258.73M▼ 67.1% | -407.23M▼ 57.4% | -546.18M▼ 34.1% | -425.81M▲ 22.0% | -529.03M▼ 24.2% | -521.66M▲ 1.4% | -447.01M▲ 14.3% | -454.12M▲ 0% |
| FCF Margin % | - | - | -637.88% | -4936.74% | -783.44% | -548.39% | -5686.62% | -235.09% | -89.03% | -80.23% |
| FCF Growth % | - | -278.05% | -67.11% | -57.4% | -34.12% | 22.04% | -24.24% | 1.39% | 14.31% | 10.86% |
| FCF per Share | -0.44 | -1.68 | -2.46 | -3.45 | -3.78 | -2.89 | -3.25 | -2.80 | -2.27 | -2.27 |
| FCF Conversion (FCF/Net Income) | 1.32x | 1.05x | 0.97x | 0.89x | 0.89x | 0.87x | 0.82x | 0.97x | 0.61x | 0.63x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 54.44M | 61.11M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BBIO Key Ratios
BridgeBio Pharma, Inc. (BBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -139.1% | -153.71% | - | - | - | - | - | 36.08% |
| Return on Invested Capital (ROIC) | - | - | -157.61% | -121.07% | -135.08% | -738.78% | - | -524% | -524% |
| Gross Margin | - | 93.84% | 100% | 95.53% | 95.58% | 73.71% | 98.25% | 94.37% | 95.08% |
| Net Margin | - | -642.1% | -5439.74% | -806.9% | -619.7% | -6913.92% | -241.44% | -145.26% | -128.25% |
| Debt / Equity | - | 0.19x | 4.60x | - | - | - | - | - | -0.01x |
| Interest Coverage | -72.11x | -31.92x | -12.79x | -11.54x | -5.03x | -7.04x | -4.46x | -12.84x | -10.41x |
| FCF Conversion | 1.05x | 0.97x | 0.89x | 0.89x | 0.87x | 0.82x | 0.97x | 0.61x | 0.63x |
| Revenue Growth | - | - | -79.66% | 745.14% | 11.38% | -88.02% | 2285.27% | 126.26% | 344.25% |
BBIO SEC Filings & Documents
BridgeBio Pharma, Inc. (BBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
BBIO Frequently Asked Questions
BridgeBio Pharma, Inc. (BBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BridgeBio Pharma, Inc. (BBIO) reported $566.0M in revenue for fiscal year 2025.
BridgeBio Pharma, Inc. (BBIO) grew revenue by 126.3% over the past year. This is strong growth.
BridgeBio Pharma, Inc. (BBIO) reported a net loss of $725.9M for fiscal year 2025.
Dividend & Returns
BridgeBio Pharma, Inc. (BBIO) had negative free cash flow of $454.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More BBIO
BridgeBio Pharma, Inc. (BBIO) financial analysis — history, returns, DCA and operating performance tools
Full BBIO Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates